If this is your company, CONTACT US to activate Packbase™ software to build your portal.
Smart Inhalers- Improving Patient Compliance and Reducing Health Care Costs
H&T Presspart are pleased to announce that they have accepted an invitation to speak at the upcoming 14th Annual Congress of International Drug Discovery Science and Technology-South Korea 2016 (IDDST-South Korea 2016) which will be held at Geyonggi of South Korea during June 16-18, 2016.
Dana Shear’s, H&T Presspart’s Sales Director for the America’s will be delivering a 30 minute speech on Smart Inhalers-Improving Patient Compliance and Reducing Health Care Costs at 14.50 during day 3 of the conference on Saturday 18th June.
The abstract of the speech is:
Rising healthcare costs are a phenomenon across the developed world and can be attributed to a combination of factors, including ageing population, and the availability of more expensive healthcare treatments.
However, data also shows that patient adherence and compliance is a major contributor. In developed countries, adherence to long-term therapies in the general population is around 50% and is much lower in developing countries. Asthma and COPD are the 5th and 6th most costly conditions in the United States today estimated at over $50 billion annually, each.
The global number of asthma and COPD suffers is growing at annual rates of 3% and 7% respectively. Recent advances in technology is enabling users and prescribers of meter dose inhalers to more effectively monitor patient compliance and adherence, including remotely. Studies have shown that these new devices can lead to a reduction in healthcare costs by validating prescribed therapies, and confirming compliance and adherence, thereby, avoiding costly visits to physicians or hospitals.
The technology, benefits, and barriers associated with developing, registering and marketing these emerging “Smart Inhalers” will be presented and discussed.
Dana will also be on hand to discuss H&T Presspart’s recently announced Connected Metered Dose Inhaler, which has been developed in partnership with Cohero Health, a leading US based digital health focused company.
The eMDI incorporates electronics into a medication inhaler to passively track and communicate medication utilization. The device incorporates a sensor to track the date and time when medication is actuated, which is then stored in onboard memory, as well as shared wirelessly via Bluetooth. It works seamlessly with Cohero Health’s platform of connected devices and mobile applications, which actively engage and empower respiratory patients by tracking medication adherence and measuring lung function.
The companies believe the eMDI, which is available for demonstration, is the first functional connected MDI ever developed. Unique features include:
- Seamless integration into Cohero Health’s connected respiratory care platform
- Onboard sensors to detect medication use as well as quality of medication administration (detection of proper inhaler actuation)
- On board electronic dose counting and display
- Modular design enabling sensing and communication capabilities to be easily be applied to additional form factors
- Compatibility with any valve and canister
- Lack of disruption to medication delivery geometry, reducing regulatory pathway and time to market